Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma

Therapeutics and Clinical Risk Management

Volumn 5, Issue 1, 2009, Pages 151-159

  Shah, Jatin J ^a   Orlowski, Robert Z ^a   Thomas, Sheeba K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bortezomib; Doxil ; Multiple myeloma; Pegylated liposomal doxorubicin; Relapsed refractory; Velcade

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; THALIDOMIDE;

CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DIARRHEA; DRUG ACTIVITY; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; MULTIPLE MYELOMA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE;

EID: 74249123929     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Kane RC, Bross PF, Farrell AT, et al. Velcade: US FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist. 2003;8(6):508-513.
2. Kane RC, Farrell AT, Sridhara R, et al. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res. 2006;12(10):2955-60.
3. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. [see comment]. New Engl J Med. 2003;348(26):2609-2617.
4. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. [see comment]. New Engl J Med. 2005;352(24):2487-2498.
5. Richardson PG, Sonneveld P, Schuster MW, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007;110(10):3557-3560.
6. Alberts DS, Salmon SE. Adriamycin (NSC-123127) in the treatment of alkylator-resistant multiple myeloma: a pilot study. Cancer Chemother Rep. 1975;59(2 Pt 1):345-350.
7. Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol. 1990;33(2):86-89.
8. Anderson H, Scarffe JH, Ranson M, et al. VAD chemotherapy as remission induction for multiple myeloma. Br J Cancer. 1995;71(2):326-330.
9. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med. 1984;310(21):1353-1356.
10. Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood. 2005;106(1):35-39.
11. Segeren CM, Sonneveld P, van der Holt B, et al. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. Br J Haematol. 1999;105(1):127-130.
12. Rifkin RM, Gregory SA, Mohrbacher A, et al. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial. Cancer. 2006;106(4):848-858.
13. Zervas K, Dimopoulos MA, Hatzicharissi E, et al. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. Ann Oncol. 2004;15(1):134-138.
14. Ferrazzi E, Woynarowski JM, Arakali A. et al. DNA damage and cytotoxicity induced by metabolites of anthracycline antibiotics, doxorubicin and idarubicin. Cancer Commun. 1991;3(6):173-180.
15. Foglesong PD, Reckord C, Swink S. Doxorubicin inhibits human DNA topoisomerase I. Cancer Chemother Pharmacol. 1992;30(2):123-125.
16. Facchinetti T, Mantovani A, Cantoni L, Cantoni R, Salmona M. Intercalation with DNA is a prerequisite for daunomycin, adriamycin and its congeners in inhibiting DNAase I. Chem Biol Interact. 1978;20(1):97-102.
17. Fornari FA, Randolph JK, Yalowich JC, Ritke MK, Gewirtz DA. Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol. 1994;45(4):649-656.
18. Momparler RL, Karon M, Siegel SE, Avila F. Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res. 1976;36(8):2891-2895.
19. Eliot H, Gianni L, Myers C. Oxidative destruction of DNA by the adriamycin-iron complex. Biochemistry. 1984;23(5):928-936.
20. Myers C, Gianni L, Zweier J, Muindi J, Sinha BK, Eliot H, et al. Role of iron in adriamycin biochemistry. Fed Proc. 1986;45(12): 2792-2797.
21. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999;59(11):2615-2622.
22. Orlowski RZ. The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Differ. 1999;6(4):303-313.
23. Hideshima T, Chauhan D, Richardson P, et al. NF-kappaB as a therapeutic target in multiple myeloma. J Biol Chem. 2002;277(19): 16639-16647.
24. Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood. 2003;101(4):1530-1534.
25. Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A. 2002;99(22):14374-14379.
26. Rajkumar SV, Richardson PG, Hideshima T, et al. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol. 2005;23(3):630-639.
27. Ambudkar SV, Kimchi-Sarfaty C, Sauna Z, et al. P-glycoprotein: from genomics to mechanism. Oncogene. 2003;22(47):7468-7485.
28. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61(7):3071-3076.
29. Ma MH, Yang HH, Parker K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res. 2003;9(3):1136-1144.
30. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003;101(6):2377-2380.
31. Orlowski RZ, and Baldwin Jr AS. NF-kappaB as a therapeutic target in cancer. Trends Mol Med. 2002;8(8):385-389.
32. Wang CY, Mayo MW, Baldwin AS Jr TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. [see comment]. Science. 1996;274(5288):784-787.
33. Fujita T, Washio K, Takabatake D, et al. Proteasome inhibitors can alter the signaling pathways and attenuate the P-glycoprotein-mediated multidrug resistance. Int J Cancer. 2005;117(4):670-682.
34. Small GW, Shi YY, Edmund NA, et al. Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role. Mol Pharmacol. 2004;66(6):1478-1490.
35. Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase I trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood. 2005;105(8):3058-3065.
36. Biehn SE, Moore DT, Voorhees PM, et al. Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin. Ann Hematol. 2007;86(3):211-216.
37. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25(25):3892-3901.
38. Ning YM, Nagher R, Sridhara R, et al. Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma. Oncology (Williston Park). 2007;21(12): 1503-1508; discussion 1511, 1513, 1516 passim.
39. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol. 1998;102(5):1115-1123.
40. Braccalenti G, Ferrara P, Gubbiotti M, et al. Antitumor activity of bortezomib-pegylated liposomal doxorubicine association as salvage therapy in multiple myeloma patients. Blood. 2007;110:4832.
41. San Miguel J, Hajek R, Nagler A, et al. Doxil + velcade in previously treated myeloma patients aged >65. Haematologica. 2007;97(6 Suppl 2):159 abstract #620.
42. Hajek R, Nagler A, Sonneveld P, et al. Doxil + velcade in previously treated high risk myeloma. Haematologica. 2007;97(6 Suppl 2):162 abstract #629.
43. Nagler A, Sonneveld P, Spencer A, et al. Doxil + velcade in previously treated myeloma patients with prior stem cell transplant. Haematologica. 2007;97(6 Suppl 2):161 abstract #625.
44. Blade J, San Miguel J, Nagler A, et al. The prolonged time to progression with pegylated liposomal doxorubicin + bortezomib versus bortezomib alone in relapsed or refractory multiple myeloma is unaffected by extent of prior therapy or previous anthracycline exposure. Blood. 2007;110(11):410.
45. Sonneveld P, Hajek R, Nagler A, et al. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/ lenalidomide therapy. Cancer. 2008;112(7):1529-15237.
46. Sutherland HJ, Blade J, San Miguel J, et al. Effect of disease stage and time since diagnosis on time to progression for pegylated liposomal doxorubicin + bortezomib vs bortezomib alone in relapsed or refractory multiple myeloma. Blood. 2007;110(11):2740.
47. Kumar S, Blade J, San Miguel J, et al. Pegylated liposomal doxorubicin (PLD) in combination with bortezomib (B) may provide therapeutic advantage for high-risk multiple myeloma patients relapsing within 12 months of stem cell transplant. Blood. 2007;110(11):2730.
48. Jakubowiak AJ, Friedman J, Kendall T, et al. A phase II study of combination of bortezomib, liposomal doxorubicin, and dexamethasone (VDD) as first line therapy for multiple myeloma. J Clin Oncol. 2006 ASCO Annual Meeting Proceedings Part I, 2006;24(18S):17504.
49. Offidani M, Bringhen S, Corvatta L, et al. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma. Eur J Haematol. 2007;78(4):297-302.
50. Duryea BGM, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-1473.
51. Offidani M, Polloni C, Corvatta L, et al. ThaDD-V treatment for patients with relapsed/refractory multiple myeloma: a feasibility/activity study. Blood. 2007;110(11):2729.
52. Chanan-Khan AA, Padmanabhan S, Miller KC, et al. Final results of a phase II study of bortezomib (Velcade) in combination with liposomal doxorubicin (Doxil) and thalidomide (VDT) demonstrate a sustained high response rates in patients (pts) with relapsed (rel) or refactory (ref) multiple myeloma. Blood. 2006;108:3539.
53. Chari A, Kaplan L, Linker C, et al. Phase I/II study of bortezomib in combination with liposomal doxorubicin and melphalan in relapsed or refractory multiple myeloma. Blood. 2005;106:5182.
54. Ries LAG, Melbert D, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD, SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975-2005/, 2007.
55. Orlowski RZ, Peterson BL, Sanford B, et al. Bortezomib and pegylated liposomal doxorubicin as induction therapy for adult patients with symptomatic multiple myeloma: Cancer and Leukemia Group B Study 10301. Blood. 2006;108(11):797.